Protagonist Therapeutics, Inc (PTGX) Free cash flow
- Free cash flow · 12 months (USD): Value $130.58M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $130.58M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $131.20M − $615.00K ≈ $130.58M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $131.20M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.58× | Operating cash flow / net income. Period ending 2026-06-30. $131.20M ÷ $82.91M ≈ 1.58× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 131.20M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 615.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 130.58M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 82.91M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $130.58M | (m) | $131.20M | $615.00K | (m) | (m) | (m) | $82.91M | (m) | (m) | (m) | 1.58× |
| 2026-03-31 | $-117.89M | (m) | $-116.64M | $1.26M | (m) | (m) | (m) | $-114.71M | (m) | (m) | (m) | 1.02× |
| 2025-12-31 | $56.08M | (m) | $57.67M | $1.59M | (m) | (m) | (m) | $-130.15M | (m) | (m) | (m) | -0.44× |
| 2025-09-30 | $63.71M | (m) | $65.47M | $1.76M | (m) | (m) | (m) | $45.91M | (m) | (m) | (m) | 1.43× |
| 2025-06-30 | $37.10M | (m) | $39.54M | $2.44M | (m) | (m) | (m) | $52.04M | (m) | (m) | (m) | 0.76× |
| 2025-03-31 | $335.29M | (m) | $336.94M | $1.66M | (m) | (m) | (m) | $56.19M | (m) | (m) | (m) | 6.00× |
| 2024-12-31 | $182.80M | (m) | $184.15M | $1.35M | (m) | (m) | (m) | $275.19M | (m) | (m) | (m) | 0.67× |
| 2024-09-30 | $229.23M | (m) | $230.29M | $1.06M | (m) | (m) | (m) | $170.85M | (m) | (m) | (m) | 1.35× |
| 2024-06-30 | $230.85M | (m) | $231.54M | $693.00K | (m) | (m) | (m) | $169.95M | (m) | (m) | (m) | 1.36× |
| 2024-03-31 | $-64.16M | (m) | $-63.32M | $841.00K | (m) | (m) | (m) | $162.11M | (m) | (m) | (m) | -0.39× |
| 2023-12-31 | $-70.84M | (m) | $-70.24M | $609.00K | (m) | (m) | (m) | $-78.95M | (m) | (m) | (m) | 0.89× |
| 2023-09-30 | $-119.49M | (m) | $-118.83M | $660.00K | (m) | (m) | (m) | $-140.48M | (m) | (m) | (m) | 0.85× |
| 2023-06-30 | $-117.84M | (m) | $-117.42M | $418.00K | (m) | (m) | (m) | $-137.61M | (m) | (m) | (m) | 0.85× |
| 2023-03-31 | $-105.35M | (m) | $-104.82M | $532.00K | (m) | (m) | (m) | $-140.19M | (m) | (m) | (m) | 0.75× |
| 2022-12-31 | $-108.93M | (m) | $-108.14M | $795.00K | (m) | (m) | (m) | $-127.39M | (m) | (m) | (m) | 0.85× |
| 2022-09-30 | $-104.36M | (m) | $-103.44M | $921.00K | (m) | (m) | (m) | $-130.11M | (m) | (m) | (m) | 0.80× |
| 2022-06-30 | $-107.73M | (m) | $-106.71M | $1.02M | (m) | (m) | (m) | $-132.68M | (m) | (m) | (m) | 0.80× |
| 2022-03-31 | $-118.01M | (m) | $-116.78M | $1.23M | (m) | (m) | (m) | $-122.48M | (m) | (m) | (m) | 0.95× |
| 2021-12-31 | $-108.97M | (m) | $-107.86M | $1.10M | (m) | (m) | (m) | $-125.55M | (m) | (m) | (m) | 0.86× |
| 2021-09-30 | $-100.82M | (m) | $-99.79M | $1.03M | (m) | (m) | (m) | $-107.53M | (m) | (m) | (m) | 0.93× |
| 2021-06-30 | $-88.45M | (m) | $-87.61M | $840.00K | (m) | (m) | (m) | $-81.49M | (m) | (m) | (m) | 1.08× |
| 2021-03-31 | $-85.86M | (m) | $-85.39M | $473.00K | (m) | (m) | (m) | $-70.07M | (m) | (m) | (m) | 1.22× |
| 2020-12-31 | $-72.95M | (m) | $-72.48M | $471.00K | (m) | (m) | (m) | $-66.15M | (m) | (m) | (m) | 1.10× |
| 2020-09-30 | $-68.47M | (m) | $-67.91M | $564.00K | (m) | (m) | (m) | $-64.77M | (m) | (m) | (m) | 1.05× |
| 2020-06-30 | $-66.05M | (m) | $-65.86M | $180.00K | (m) | (m) | (m) | $-73.41M | (m) | (m) | (m) | 0.90× |
| 2020-03-31 | $-41.65M | (m) | $-40.71M | $939.00K | (m) | (m) | (m) | $-83.16M | (m) | (m) | (m) | 0.49× |
| 2019-12-31 | $-42.49M | (m) | $-41.53M | $967.00K | (m) | (m) | (m) | $-77.19M | (m) | (m) | (m) | 0.54× |
| 2019-09-30 | $-38.18M | (m) | $-37.37M | $811.00K | (m) | (m) | (m) | $-73.55M | (m) | (m) | (m) | 0.51× |
| 2019-06-30 | $-33.67M | (m) | $-32.40M | $1.27M | (m) | (m) | (m) | $-65.88M | (m) | (m) | (m) | 0.49× |
| 2019-03-31 | $-51.91M | (m) | $-51.47M | $444.00K | (m) | (m) | (m) | $-45.37M | (m) | (m) | (m) | 1.13× |
| 2018-12-31 | $-50.43M | (m) | $-49.95M | $486.00K | (m) | (m) | (m) | $-38.92M | (m) | (m) | (m) | 1.28× |
| 2018-09-30 | $-54.44M | (m) | $-53.96M | $480.00K | (m) | (m) | (m) | $-28.11M | (m) | (m) | (m) | 1.92× |
| 2018-06-30 | $-4.50M | (m) | $-3.98M | $522.00K | (m) | (m) | (m) | $-24.20M | (m) | (m) | (m) | 0.16× |
| 2018-03-31 | $-1.74M | (m) | $-910.00K | $826.00K | (m) | (m) | (m) | $-30.52M | (m) | (m) | (m) | 0.03× |
| 2017-12-31 | $3.21M | (m) | $3.87M | $666.00K | (m) | (m) | (m) | $-36.96M | (m) | (m) | (m) | -0.10× |
| 2017-09-30 | $7.65M | (m) | $8.34M | $694.00K | (m) | (m) | (m) | $-45.15M | (m) | (m) | (m) | -0.18× |
| 2017-06-30 | $-39.86M | (m) | $-39.34M | $520.00K | (m) | (m) | (m) | $-47.41M | (m) | (m) | (m) | 0.83× |
| 2017-03-31 | $-35.27M | (m) | $-35.09M | $176.00K | (m) | (m) | (m) | $-39.53M | (m) | (m) | (m) | 0.89× |
| 2016-12-31 | $-30.35M | (m) | $-29.97M | $379.00K | (m) | (m) | (m) | $-37.18M | (m) | (m) | (m) | 0.81× |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-23.91M | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-14.78M | (m) | $-14.38M | $399.00K | (m) | (m) | (m) | $-14.86M | (m) | (m) | (m) | 0.97× |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-8.04M | (m) | $-7.74M | $299.00K | (m) | (m) | (m) | $-11.07M | (m) | (m) | (m) | 0.70× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |